Related coverage linked through entity extraction aliases.
Feb 21, 2026
The US FDA has accepted Dr Reddy's Biologics License Application for DRL-AB, a proposed interchangeable biosimilar to Orencia (abatacept) for intravenous infusion, marking the first abatacept biosimilar submission.
Feb 21, 2026
Dr. Reddy's Laboratories has received FDA acceptance for its biosimilar application targeting Bristol-Myers Squibb's Orencia, marking the first U.S. application for an off-patent version of the arthritis treatment that generated $2.7 billion in 2025.
Feb 19, 2026
Scientists at Northwell Health's Feinstein Institutes have developed a novel drug discovery strategy transforming a detrimental immune element into a therapeutic for sepsis and rheumatoid arthritis, published in Military Medical Research.
Feb 16, 2026
The global biopharmaceutical industry entered 2026 facing one of the largest waves of patent expirations in its history, with $200-300 billion in yearly sales at risk through 2032 as major drugs lose exclusivity.
Feb 14, 2026
Eli Lilly achieved positive outcomes for nearly all R&D key events in 2025 and acquired Orna Therapeutics for $2.4 billion to develop circular RNA therapies for autoimmune diseases.
Feb 14, 2026
Eli Lilly acquired Orna Therapeutics for $2.4 billion and announced multiple partnerships while investing in AI drug discovery infrastructure, including building the industry's largest AI supercomputer to boost clinical trial success rates.
Feb 13, 2026
Engineered regulatory T cell therapies are progressing through clinical trials for autoimmune diseases and organ transplant rejection, with CAR-Treg candidates showing promising early results in rheumatoid arthritis and other conditions.
Feb 13, 2026
Eli Lilly announced a $2.4 billion acquisition of Orna Therapeutics and multiple partnerships to expand its drug pipeline beyond its blockbuster GLP-1 franchise into cell and genetic therapies.
Feb 13, 2026
The European Commission has granted marketing authorization for Gotenfia, a golimumab biosimilar to Simponi, developed by Bio-Thera and to be commercialized by STADA across the EU, EEA, UK, Switzerland and selected other countries.
Feb 13, 2026
The European Commission has approved Gotenfia (golimumab), a biosimilar to Simponi developed by Bio-Thera and marketed by STADA, for chronic inflammatory autoimmune diseases across the EU and EEA.
